Li, Hang-Long, Lip, Gregory-Y H 
ORCID: 0000-0002-7566-1626, Feng, Qi, Fei, Yue, Tse, Yi-Kei, Wu, Mei-Zhen, Ren, Qing-Wen, Tse, Hung-Fat, Cheung, Bernard-M Y and Yiu, Kai-Hang
(2021)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
CARDIOVASCULAR DIABETOLOGY, 20 (1).
100-.
|
PDF
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias a systematic review and meta-analysis.pdf - Open Access published version Download (1MB) | Preview |
Abstract
<h4>Background</h4>Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regarding the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the risk of developing arrhythmias. This study aims to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF, DM, or CKD.<h4>Methods</h4>MEDLINE, EMBASE, and ClinicalTrials.gov were searched from inception up to 27 August 2020. Randomized controlled trials that randomized patients with DM, CKD, or HF to SGLT2i or placebo were included. The outcomes of interest include atrial fibrillation (AF), embolic stroke, atrial flutter (AFL), AF/AFL, ventricular tachycardia (VT), and cardiac arrest. Relative risks (RRs) and 95% confidence intervals (CI) were pooled using a random-effects model.<h4>Results</h4>Out of 4,532 citations, 22 trials with altogether 52,115 patients were included (mean age 63.2 years; 33,747 [64.8%] of participants were men). SGLT2i were associated with a lower risk of AF (RR 0.82, 95% CI 0.70-0.96), embolic stroke (RR 0.32, 95% CI 0.12-0.85), AF/AFL (RR 0.82, 95% CI 0.71-0.95), and VT (RR 0.73, 95% CI 0.53-0.99), while the risk reductions in AFL (RR 0.83, 95% CI 0.58-1.17) and cardiac arrest (RR 0.83, 95% CI 0.61-1.14) did not reach statistical significance. The associations appeared to be consistent across different baseline conditions (DM vs CKD vs HF; atherosclerotic cardiovascular disease [ASCVD] vs no ASCVD) and the SGLT2i used.<h4>Conclusions</h4>SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by which SGLT2i protect against arrhythmias.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SGLT2 inhibitors, Arrhythmia, Atrial fibrillation |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 12 Oct 2023 14:25 |
| Last Modified: | 12 Oct 2023 14:25 |
| DOI: | 10.1186/s12933-021-01293-8 |
| Open Access URL: | https://doi.org/10.1186/s12933-021-01293-8 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3173636 |
Dimensions
Dimensions
